Liposomal Products Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, China, Japan, Germany, France - Size and Forecast 2023-2027

Published: Feb 2023 Pages: 163 SKU: IRTNTR71397

Liposomal Products Market Forecast 2023-2027

The Liposomal Products Market is estimated to grow by USD 3,183.63 million at a CAGR of 9.65% during the forecast period.

The growth of the market depends on several factors, including the rising incidence of fungal disorders, the growing prevalence of cancer cases, and many side effects associated with cancer treatment. However, late diagnosis and poor survival rates of patients with cancer are major challenges in the liposome drug delivery market. Companies are increasingly focussing on the market trends such as strategic alliances, and rising adoption of quality by design (QbD) over traditional processes to overcome the challenges.

What will be the Market Size During the Forecast Period?

To learn more about this report, Request Free Sample

Market Dynamics

Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Drivers

The growing prevalence of cancer cases is a major market driver. Cancer is a common chronic disease and a growing health issue globally, caused by genetic mutations, environmental factors like smoking and pollution, and changing diets. This has led to a rise in cancer cases and deaths, making it the second leading cause of death worldwide.

Breast, prostate, and lung cancers are prevalent in North America and Europe, with breast cancer now the most commonly diagnosed type globally. Accurate registration of cancer patients is crucial for medical research and healthcare planning. As cancer incidence and prevalence increase, the demand is expected to grow, driving market growth.

Significant Trends

The rising adoption of quality by design (QbD) over traditional processes is the primary trend in the market. The adoption of rational-based approaches such as QbD over empirical and simulation-based approaches has been contributing to streamlined processes. QbD is based on a fact-based rational approach and helps manufacturing companies for better robust decision-making as compared to traditional approaches based on trial and error. Moreover, the global regulatory authorities are converging toward process and regulatory harmonization for the manufacturing of liposomal formulation.

The QbD approach is expected to witness increased popularity and rising adoption. The adoption of QbD in manufacturing processes is likely to contribute towards better quality, gradation, and consistency of excipient supply, which, in turn, will lead to better final products or drugs. Thus the rising adoption of QbD will further enhance the growth of the liposome drug delivery market during the forecast period.

Major Challenges

Late diagnosis and poor survival rate of patients with cancer is the major challenge impeding the liposome drug delivery market growth. Almost half of cancer patients are diagnosed at late stages as per the NHS, in the UK. In the late stages of cancer, it becomes difficult to control tumor growth. The late diagnosis at the primary care level occurs because of the failure to recognize and investigate the symptoms of cancer. This is because most patients with cancer show non-specific symptoms, which are difficult for primary healthcare physicians to analyze and identify. Similarly, at the secondary care level, the lack of adequate treatment contributes to the poor diagnosis and survival of patients with cancer.

During the late stages, the treatment of cancer using drug therapies becomes difficult, and surgery is often performed in such cases. Hence, the late diagnosis and the poor survival rate associated with cancer limit the use of liposomal products as well as increase the mortality rates associated with cancer. Hence, such factors may hamper the growth of the liposomal drugs market during the forecast period.

Key Customer Landscape

The market research and growth report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market growth and forecasting report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Customer Landscape

Who are the Major Liposomal Products Market Companies?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the liposome drug delivery market.

Galen-pharma - The company offers liposomal product solutions such as DaunoXome. The company offers products under the categories of pain management, dermatology, and gastroenterology.

The market growth analysis report also includes detailed analyses of the competitive landscape of the market and information about 15 market Companies, including:

  • GENFIT SA
  • Gilead Sciences Inc.
  • Innocan Pharma Corp. Ltd.
  • Johnson and Johnson Services Inc.
  • Leadiant Biosciences Inc.
  • Lipella Pharmaceuticals Inc.
  • Liposoma B.V.
  • Merrimack Pharmaceuticals Inc.
  • Nanovex Biotechnologies SL
  • Pacira BioSciences Inc.
  • Spectrum Pharmaceuticals Inc.
  • Taiwan Liposome Co. Ltd.
  • The Lubrizol Corp.
  • Vascular Biosciences
  • Viatris Inc.

Qualitative and quantitative analysis of Companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize Companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize Companies as dominant, leading, strong, tentative, and weak.

Market Segmentation

The liposome drug delivery market share growth of the cancer segment will be significant during the forecast period. Liposomal products are increasingly used in cancer therapy. Advancements in liposomal vesicle development have achieved both targeted drug delivery and controlled drug release. This property of liposomes is necessarily helpful for cancer treatment. Therefore rising cases of cancer diagnosis will fuel the market growth during the forecast period.

Get a glance at the market contribution of various segments Request a PDF Sample

The cancer segment was valued at USD 1,825.69 million in 2017 and continued to grow until 2021. Liposomal drug delivery systems are used as targeted therapy for cancer treatment in surgical resection, chemotherapy, and radiation therapy. Therefore, the rise in the cancer incidence rate globally is expected to enhance the demand during the forecast period.

Regional Analysis

For more insights on the market share of various regions Request PDF Sample now!

North America is estimated to contribute 36% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

North America holds the largest share of the global liposomal products market owing to the huge investments made in the oncology sector in the US. The US dominates the regional market and acts as the major revenue generator, followed by Canada. Huge investments in the pharmaceutical industry, specifically the oncology sector, and the presence of pharmaceutical giants in the region are some of the major factors backing the dominance of the US.

Cancer is one of the most common chronic diseases in the US. Also, in every 100,000 population, 436 new cancer cases were reported, and about 156 died of cancer in the country. Thus, with the growing incidences of cancer, Companies will invest in extensive research to develop effective drugs for the treatment of several cancers. As cancer drugs are associated with several side effects, the demand is expected to increase in the region during the forecast period.

Market Analyst Overview

The Liposomal Products Market offers promising advancements in drug delivery, enhancing the efficacy of therapeutic compounds through improved cellular and tissue uptake and biodistribution while mitigating systemic toxicity. With unique physicochemical and biophysical properties, liposomal formulations attract the attention of drug manufacturers seeking novel solutions for various ailments, including diabetes. Organizations like the International Diabetes Federation (IDF) explore the potential of liposomal diabetes therapeutics to revolutionize treatment approaches. Evonik Health Care's LIPEX liposome extruder facilitates innovation in the liposomal drug delivery market, adhering to stringent regulatory policies. Moreover, liposomes exhibit promise in cancer therapeutics, as highlighted by research from the Australian Institute of Health and Welfare (AIHW) and the Canadian Medical Association Journal, offering pharmacological merits and advantages in anticancer treatment. As research studies continue to unravel the benefits of liposomal formulations, their role in revolutionizing drug delivery is poised to expand further.

Segment Overview

The market forecasting report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

  • Application Outlook (USD Million, 2017 - 2027)
    • Cancer
    • Fungal infections
    • Pain management
    • Viral vaccines
    • Photodynamic therapy
  • Type Outlook (USD Million, 2017 - 2027)
    • Branded
    • Generic
  • Region Outlook (USD Million, 2017 - 2027)
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • Rest of World (ROW)
      • Brazil
      • Argentina
      • Rest of the Middle East & Africa

Liposomal Products Market Scope

Report Coverage

Details

Page number

163

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 9.65%

Market growth 2023-2027

USD 3,183.63 million

Market structure

Fragmented

YoY growth 2022-2023(%)

8.8

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 36%

Key countries

US, China, Japan, Germany, and France

Competitive landscape

 Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

Key companies profiled

Acthera Therapeutics AG, Bausch Health Companies Inc., Baxter International Inc., Galen Ltd., GENFIT SA, Gilead Sciences Inc., Innocan Pharma Corp. Ltd., Johnson and Johnson Services Inc., Leadiant Biosciences Inc., Lipella Pharmaceuticals Inc., Liposoma B.V., Merrimack Pharmaceuticals Inc., Nanovex Biotechnologies SL, Pacira BioSciences Inc., Spectrum Pharmaceuticals Inc., Taiwan Liposome Co. Ltd., Takeda Pharmaceutical Co. Ltd., The Lubrizol Corp., Vascular Biosciences, and Viatris Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period

Customization purview

If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request Free sample

What are the Key Data Covered in this Market Research Report?

  • CAGR of the liposome drug delivery market during the forecast period
  • Detailed information on factors that will drive the growth of the market between 2023 and 2027
  • Precise estimation of the market size and its contribution to the parent market
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the industry across North America, Europe, Asia, and Rest of World (ROW)
  • Thorough analysis of the market’s competitive landscape and detailed information about Companies
  • Comprehensive analysis of factors that will challenge the growth of the market Companies

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global liposomal products market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on Global liposomal products market 2017 - 2021 ($ billion)
    • 4.2 Application Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Application Segment 2017 - 2021 ($ billion)
    • 4.3 Type Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Type Segment 2017 - 2021 ($ billion)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ billion)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ billion)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Application

    • 6.1 Market segments
      • Exhibit 30: Chart on Application - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on Application - Market share 2022-2027 (%)
    • 6.2 Comparison by Application
      • Exhibit 32: Chart on Comparison by Application
      • Exhibit 33: Data Table on Comparison by Application
    • 6.3 Cancer - Market size and forecast 2022-2027
      • Exhibit 34: Chart on Cancer - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 35: Data Table on Cancer - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 36: Chart on Cancer - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on Cancer - Year-over-year growth 2022-2027 (%)
    • 6.4 Fungal infections - Market size and forecast 2022-2027
      • Exhibit 38: Chart on Fungal infections - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 39: Data Table on Fungal infections - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 40: Chart on Fungal infections - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on Fungal infections - Year-over-year growth 2022-2027 (%)
    • 6.5 Pain management - Market size and forecast 2022-2027
      • Exhibit 42: Chart on Pain management - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 43: Data Table on Pain management - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 44: Chart on Pain management - Year-over-year growth 2022-2027 (%)
      • Exhibit 45: Data Table on Pain management - Year-over-year growth 2022-2027 (%)
    • 6.6 Viral vaccines - Market size and forecast 2022-2027
      • Exhibit 46: Chart on Viral vaccines - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 47: Data Table on Viral vaccines - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 48: Chart on Viral vaccines - Year-over-year growth 2022-2027 (%)
      • Exhibit 49: Data Table on Viral vaccines - Year-over-year growth 2022-2027 (%)
    • 6.7 Photodynamic therapy - Market size and forecast 2022-2027
      • Exhibit 50: Chart on Photodynamic therapy - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 51: Data Table on Photodynamic therapy - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 52: Chart on Photodynamic therapy - Year-over-year growth 2022-2027 (%)
      • Exhibit 53: Data Table on Photodynamic therapy - Year-over-year growth 2022-2027 (%)
    • 6.8 Market opportunity by Application
      • Exhibit 54: Market opportunity by Application ($ billion)

    7 Market Segmentation by Type

    • 7.1 Market segments
      • Exhibit 55: Chart on Type - Market share 2022-2027 (%)
      • Exhibit 56: Data Table on Type - Market share 2022-2027 (%)
    • 7.2 Comparison by Type
      • Exhibit 57: Chart on Comparison by Type
      • Exhibit 58: Data Table on Comparison by Type
    • 7.3 Branded - Market size and forecast 2022-2027
      • Exhibit 59: Chart on Branded - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 60: Data Table on Branded - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 61: Chart on Branded - Year-over-year growth 2022-2027 (%)
      • Exhibit 62: Data Table on Branded - Year-over-year growth 2022-2027 (%)
    • 7.4 Generic - Market size and forecast 2022-2027
      • Exhibit 63: Chart on Generic - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 64: Data Table on Generic - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 65: Chart on Generic - Year-over-year growth 2022-2027 (%)
      • Exhibit 66: Data Table on Generic - Year-over-year growth 2022-2027 (%)
    • 7.5 Market opportunity by Type
      • Exhibit 67: Market opportunity by Type ($ billion)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 68: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 69: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 70: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 71: Chart on Geographic comparison
      • Exhibit 72: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 73: Chart on North America - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 74: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 75: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 76: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Europe - Market size and forecast 2022-2027
      • Exhibit 77: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 78: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 79: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 80: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 81: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 82: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 83: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 84: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 85: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 86: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 87: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 88: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 89: Chart on US - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 90: Data Table on US - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 91: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 92: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 Germany - Market size and forecast 2022-2027
      • Exhibit 93: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 94: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 95: Chart on Germany - Year-over-year growth 2022-2027 (%)
      • Exhibit 96: Data Table on Germany - Year-over-year growth 2022-2027 (%)
    • 9.9 China - Market size and forecast 2022-2027
      • Exhibit 97: Chart on China - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 98: Data Table on China - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 99: Chart on China - Year-over-year growth 2022-2027 (%)
      • Exhibit 100: Data Table on China - Year-over-year growth 2022-2027 (%)
    • 9.10 France - Market size and forecast 2022-2027
      • Exhibit 101: Chart on France - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 102: Data Table on France - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 103: Chart on France - Year-over-year growth 2022-2027 (%)
      • Exhibit 104: Data Table on France - Year-over-year growth 2022-2027 (%)
    • 9.11 Japan - Market size and forecast 2022-2027
      • Exhibit 105: Chart on Japan - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 106: Data Table on Japan - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 107: Chart on Japan - Year-over-year growth 2022-2027 (%)
      • Exhibit 108: Data Table on Japan - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 109: Market opportunity by geography ($ billion)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 110: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 111: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 112: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 113: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 114: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 115: Matrix on vendor position and classification
            • 12.3 Acthera Therapeutics AG
              • Exhibit 116: Acthera Therapeutics AG - Overview
              • Exhibit 117: Acthera Therapeutics AG - Product / Service
              • Exhibit 118: Acthera Therapeutics AG - Key offerings
            • 12.4 Bausch Health Companies Inc.
              • Exhibit 119: Bausch Health Companies Inc. - Overview
              • Exhibit 120: Bausch Health Companies Inc. - Business segments
              • Exhibit 121: Bausch Health Companies Inc. - Key news
              • Exhibit 122: Bausch Health Companies Inc. - Key offerings
              • Exhibit 123: Bausch Health Companies Inc. - Segment focus
            • 12.5 Baxter International Inc.
              • Exhibit 124: Baxter International Inc. - Overview
              • Exhibit 125: Baxter International Inc. - Business segments
              • Exhibit 126: Baxter International Inc. - Key news
              • Exhibit 127: Baxter International Inc. - Key offerings
              • Exhibit 128: Baxter International Inc. - Segment focus
            • 12.6 Galen Ltd.
              • Exhibit 129: Galen Ltd. - Overview
              • Exhibit 130: Galen Ltd. - Product / Service
              • Exhibit 131: Galen Ltd. - Key offerings
            • 12.7 Gilead Sciences Inc.
              • Exhibit 132: Gilead Sciences Inc. - Overview
              • Exhibit 133: Gilead Sciences Inc. - Product / Service
              • Exhibit 134: Gilead Sciences Inc. - Key news
              • Exhibit 135: Gilead Sciences Inc. - Key offerings
            • 12.8 Innocan Pharma Corp. Ltd.
              • Exhibit 136: Innocan Pharma Corp. Ltd. - Overview
              • Exhibit 137: Innocan Pharma Corp. Ltd. - Product / Service
              • Exhibit 138: Innocan Pharma Corp. Ltd. - Key offerings
            • 12.9 Johnson and Johnson Services Inc.
              • Exhibit 139: Johnson and Johnson Services Inc. - Overview
              • Exhibit 140: Johnson and Johnson Services Inc. - Business segments
              • Exhibit 141: Johnson and Johnson Services Inc. - Key news
              • Exhibit 142: Johnson and Johnson Services Inc. - Key offerings
              • Exhibit 143: Johnson and Johnson Services Inc. - Segment focus
            • 12.10 Leadiant Biosciences Inc.
              • Exhibit 144: Leadiant Biosciences Inc. - Overview
              • Exhibit 145: Leadiant Biosciences Inc. - Product / Service
              • Exhibit 146: Leadiant Biosciences Inc. - Key offerings
            • 12.11 Liposoma B.V.
              • Exhibit 147: Liposoma B.V. - Overview
              • Exhibit 148: Liposoma B.V. - Product / Service
              • Exhibit 149: Liposoma B.V. - Key offerings
            • 12.12 Merrimack Pharmaceuticals Inc.
              • Exhibit 150: Merrimack Pharmaceuticals Inc. - Overview
              • Exhibit 151: Merrimack Pharmaceuticals Inc. - Product / Service
              • Exhibit 152: Merrimack Pharmaceuticals Inc. - Key offerings
            • 12.13 Pacira BioSciences Inc.
              • Exhibit 153: Pacira BioSciences Inc. - Overview
              • Exhibit 154: Pacira BioSciences Inc. - Business segments
              • Exhibit 155: Pacira BioSciences Inc. - Key offerings
              • Exhibit 156: Pacira BioSciences Inc. - Segment focus
            • 12.14 Spectrum Pharmaceuticals Inc.
              • Exhibit 157: Spectrum Pharmaceuticals Inc. - Overview
              • Exhibit 158: Spectrum Pharmaceuticals Inc. - Product / Service
              • Exhibit 159: Spectrum Pharmaceuticals Inc. - Key offerings
            • 12.15 Takeda Pharmaceutical Co. Ltd.
              • Exhibit 160: Takeda Pharmaceutical Co. Ltd. - Overview
              • Exhibit 161: Takeda Pharmaceutical Co. Ltd. - Product / Service
              • Exhibit 162: Takeda Pharmaceutical Co. Ltd. - Key news
              • Exhibit 163: Takeda Pharmaceutical Co. Ltd. - Key offerings
            • 12.16 The Lubrizol Corp.
              • Exhibit 164: The Lubrizol Corp. - Overview
              • Exhibit 165: The Lubrizol Corp. - Product / Service
              • Exhibit 166: The Lubrizol Corp. - Key offerings
            • 12.17 Viatris Inc.
              • Exhibit 167: Viatris Inc. - Overview
              • Exhibit 168: Viatris Inc. - Business segments
              • Exhibit 169: Viatris Inc. - Key offerings
              • Exhibit 170: Viatris Inc. - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 171: Inclusions checklist
                • Exhibit 172: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 173: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 174: Research methodology
                • Exhibit 175: Validation techniques employed for market sizing
                • Exhibit 176: Information sources
              • 13.5 List of abbreviations
                • Exhibit 177: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              liposomal products market market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis